JUNE 20246Managing EditorAlex D'souzaVisualizerEdwin PaulMichael WayneJUNE - 17 - 2024, volume 07 - Issue 09 (ISSN 2691-4093) Published by ValleyMedia, Inc. Emailsales@medicaltechoutlook.comeditor@medicaltechoutlook.commarketing@medicaltechoutlook.comTo subscribe to Medical Tech OutlookVisit www.medicaltechoutlook.com Copyright © 2024 ValleyMedia Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.*Some of the Insights are based on the interviews with respective CIOs and CXOs to our editorial staffAlex D'souzaManaging Editoreditor@medicaltechoutlook.comCell and gene therapies witnessed multiple breakthroughs, gaining FDA approvals in 2023, with 2024 set to outshine the previous year with more authorizations for regenerative medicine treatments. Some of the game-changing disruptions set to become available include the adoptive cell therapy for solid tumours, the introduction of allogeneic T-cell therapy, and groundbreaking treatments for haemophilia A and B, along with dystrophic epidermolysis bullosa.Within the APAC region, impactful partnerships between regenerative medicine pioneers and leading pharma companies are sparking the exploration of novel applications and creating solutions that were once deemed unrealistic. Regenerative medicine is also unlocking opportunities for supply chain optimization to reshape the production and distribution of regenerative therapies to those in need. These developments are driving unprecedented market growth, with its value projected to grow with a CAGR of 21.5 percent and reach $7.9 billion by 2027.As we stand on the precipice of a new era, regenerative medicine is propelling multiple industries into uncharted territories of technological innovation. Taking this into account, organizations in the domain are recognizing the need to foster collaborations with reliable partners that can help them on their journey to make leading-edge treatments available worldwide.In this issue of MedTech Outlook APAC, we showcase Top Regenerative Medicine Solutions Providers in APAC 2024, who play a pivotal role in shaping the future of businesses. The edition includes thought leadership articles from Takehisa Yamada, President and Representative Director at EPS, and Ziad Farah, MD MBA, Chief Medical Officer, Center Light Health PACE and Adjunct Assistant Professor of Medicine, Albert Einstein University. The magazine spotlights AS Medical Support as the cover story feature. It is a biotechnology company that specializes in regenerative medicine, stem-cell therapy and cell culture products. AS Medical Support also provides consulting services to help establish regenerative medicine clinics and assists with the legal aspects, from application to after-sales support. The magazine also showcases Thailand-based Regenerative Medicine, which aims to support physicians and medical clinics in treating their patients, whether for preventive or curative purposes, anti-aging treatments, or life-saving interventions.We hope these valuable insights from the industry leaders featured in this edition will assist you in making informed decisions for your businesses.A Glimpse into the Regenerative Medicine BoomEDITORIALEditorial StaffJoe PhilipLaura PintoJoshua ParkerMerlin WatsonSarah FernandesGina ClumskyYenny TurnerTiffany Hayworth
< Page 5 | Page 7 >